The website recently uploaded an interesting article regarding a recent bio-pharmaceutical meeting in Chengdu and we summarise the major points as follows.

“On the 19th March  2016, the bio-pharmaceutical meeting of the  Venture Tianfu-Jingronghui was held in Chengdu’s Jingrong International Plaza, within the Chengdu Hi Tech Zone, with over 450 participants attending ranging, from finance institutions, government, investors, start-up companies, and universities.

The participants discussed issues ranging from emerging bio-pharmaceutical research trends and technological breakthroughs and the instrumental role of entrepreneurship and innovation to successfully commercialise these breakthroughs.

Jack Szostak, one of the three American winners of the 2009 Nobel Prize in medical physiology made a speech outlining his vision regarding nucleic acid research and his personal endeavours.

On the 16th November 2015 ,  the Chengdu High - Tech zone, signed an agreement with the 2009 Nobel Laureate, Jack Szostak,  to develop a nucleic acid research institute in Chengdu. The Institute will draw upon the ground breaking knowledge and work of fellow researchers from the Sichuan University, Harvard University, Massachusetts General Hospital (Boston) and the Georgia State University to enhance the research and development of nucleic acids.

A Chengdu Hi Zone official also stated, “The Institute will also serve as a focal point within China to encourage innovation within the nucleic medical industry and encourage all stakeholders from hospitals, and other medical research companies to find ground breaking nucleic technologies and embrace the ‘Internet + healthcare’ in their disease detection and solution processes.”

Mr. Pedro Romania, the Deputy Director from the Cuban National Biomedical Industry Group also made a keynote speech and stated, “The bio-pharmaceutical industry is in the midst of a further scientific and technological revolution and entrepreneurship and innovation will play an instrumental role in successfully commercialising these emerging bio-pharm technologies”. 

Eleven bio-pharmaceutical start-ups also made presentations to potential investors and fellow researchers of which two were from the United States, ‘Imstem’ a company focusing on the research and development of stem cell therapy, and ‘Anouca Bio-sciences’ whose founder is a Harvard Professor developing an antineoplastic anticancer SIMP structure development medications “, end article. once again congratulates, Venture Tianfu-Jingronghui, The Chengdu High-Tech Zone, its Nobel laureate attendees, start-ups, and all participants in their unique input in making the biopharmaceutical conference a super success.

Biopharmaceuticals is a totally different ballgame to your conventional pharmaceutical enterprises, which concentrates on using chemicals to develop medications, whereas biopharmaceutics utilizes biological components to produce medications such as gene therapy, stem cells and vaccines.

Nucleic medicine is a very complex and essential area of medical research because nucleic acids are the building blocks of living organisms. The most recognizable is the ‘DNA’ also known as ‘deoxyribonucleic acid’, which maintains one’s unique biological cell structure. DNA research has been fundamental in creating medical breakthroughs such as ‘insulin’, used in treating diabetes, probably one of our generation’s most lethal killer, ‘human growth hormones’ which greatly assists in human cell reproduction and regeneration. Please see further below for further information on nucleic medicine, DNA’s, Nobel Laureate Jack Szostak’s work. 

Antineoplastic or anticancer medications are medications that prevent or inhibit the development and proliferation of ‘neoplasms’. Neoplasms are an abnormal growth of human tissue which can develop into either benign or malignant caner cells.  The world cancer day website estimates about “7.6 million people die from cancer each year” and any enterprise, governmental or research effort to find cancer cures and or minimise its growth is totally commendable. Indeed long-term solutions may take further time, but Chengdu, the economic growth centre of western China, has taken this matter seriously and by creating these medical and biopharm clusters it will encourage collaboration and innovation.

Chengdu has a thriving research and development and innovation focus, and is home to over 50 universities, 30 national level research institutes and a large number of research laboratories. Chengdu also houses very reputable medical schools and hospitals such as the West China Medical Centre of Sichuan University and the  West China Second University Hospital, which specalises in women’s health. Chengdu’s medical practitioners are technically strong and experienced in a broad range of  medical prognosis matters and a centre for the growing Western Chinese populations in seeking medical help.

The Chengdu Tianfu Life Sciences Park has also been a very successful biopharmaceutical and medical research and development centre and is home to more than 200 biopharmaceutical enterprises. As clearly articulated in the press release the relevant government organs are fully supportive of the biopharmaceutical industry and their vision is to make Chengdu ‘The Western China Biopharmaceutical Innovation Hub.’

Indeed it will be those knowledgeable and talented professionals and start-ups within the biopharmaceutical and life sciences industries that take the initial steps within Chengdu will gain immense “first move advantage”.

Finally the Chengdu Municipal Government has issued the ‘ten new talent policies’, which provides benefits and incentives for these talented and knowledgeable professionals in developing their careers and start-ups within Chengdu. Just ask Jack Szostak.

Information Sources:  

Disclaimer: The first six paragraphs were summarised from the first source mentioned above and undertook significant research with our team of experienced and knowledgeable medical practitioners to ensure our readers better understand these ground breaking medical break thrus and future trends.